Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

This trial is testing a three-drug combination — revumenib, azacitidine, and venetoclax — for children and young adults with relapsed or refractory acute myeloid leukemia (AML) that carries specific genetic mutations (such as KMT2A or NUP98 rearrangements) that are targeted by revumenib. **You may be eligible if...** - You are a child or young adult with AML or a related leukemia that has relapsed (come back) or did not respond to at least two rounds of chemotherapy - Your leukemia carries one of the specific gene mutations targeted by this trial (KMT2A, NUP98, NPM1, or others listed in the protocol) - Your bone marrow has at least 5% leukemia cells confirmed - You have adequate organ function **You may NOT be eligible if...** - Your leukemia does not have one of the required genetic mutations - You do not have enough leukemia cells in the bone marrow to confirm relapse - Your organ function (liver, kidneys, heart) is too impaired for this treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.